FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385709130> ?p ?o ?g. }

• W4385709130 abstract "Inborn errors of immunity (IEIs) are considered significant challenges for children with IEIs, their families, and their medical providers. Infections are the most common complication of IEIs and children can acquire coronavirus disease 2019 (COVID-19) even when protective measures are taken.To estimate the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children with IEIs and analyse the demographic parameters, clinical characteristics and treatment outcomes in children with IEIs with COVID-19 illness.For this systematic review, we searched ProQuest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guideline for studies on the development of COVID-19 in children with IEIs, published from December 1, 2019 to February 28, 2023, with English language restriction.Of the 1095 papers that were identified, 116 articles were included in the systematic review (73 case report, 38 cohort 4 case-series and 1 case-control studies). Studies involving 710 children with IEIs with confirmed COVID-19 were analyzed. Among all 710 IEIs pediatric cases who acquired SARS-CoV-2, some children were documented to be admitted to the intensive care unit (ICU) (n = 119, 16.8%), intubated and placed on mechanical ventilation (n = 87, 12.2%), suffered acute respiratory distress syndrome (n = 98, 13.8%) or died (n = 60, 8.4%). Overall, COVID-19 in children with different IEIs patents resulted in no or low severity of disease in more than 76% of all included cases (COVID-19 severity: asymptomatic = 105, mild = 351, or moderate = 88). The majority of children with IEIs received treatment for COVID-19 (n = 579, 81.5%). Multisystem inflammatory syndrome in children (MIS-C) due to COVID-19 in children with IEIs occurred in 103 (14.5%). Fatality in children with IEIs with COVID-19 was reported in any of the included IEIs categories for cellular and humoral immunodeficiencies (n = 19, 18.6%), immune dysregulatory diseases (n = 17, 17.9%), innate immunodeficiencies (n = 5, 10%), bone marrow failure (n = 1, 14.3%), complement deficiencies (n = 1, 9.1%), combined immunodeficiencies with associated or syndromic features (n = 7, 5.5%), phagocytic diseases (n = 3, 5.5%), autoinflammatory diseases (n = 2, 3%) and predominantly antibody deficiencies (n = 5, 2.5%). Mortality was COVID-19-related in a considerable number of children with IEIs (29/60, 48.3%). The highest ICU admission and fatality rates were observed in cases belonging to cellular and humoral immunodeficiencies (26.5% and 18.6%) and immune dysregulatory diseases (35.8% and 17.9%) groups, especially in children infected with SARS-CoV-2 who suffered severe combined immunodeficiency (28.6% and 23.8%), combined immunodeficiency (25% and 15%), familial hemophagocytic lymphohistiocytosis (40% and 20%), X-linked lymphoproliferative diseases-1 (75% and 75%) and X-linked lymphoproliferative diseases-2 (50% and 50%) compared to the other IEIs cases.Children with IEIs infected with SARS-CoV-2 may experience higher rates of ICU admission and mortality in comparison with the immunocompetent pediatric populations. Underlying immune defects does seem to be independent risk factors for severe SARS-CoV-2 infection in children with IEIs, a number of children with SCID and CID were reported to have prolonged infections-though the number of patients is small-but especially immune dysregulation diseases (XLP1 and XLP2) and innate immunodeficiencies impairing type I interferon signalling (IFNAR1, IFNAR2 and TBK1)." @default.
• W4385709130 created "2023-08-10" @default.
• W4385709130 creator A5003377819 @default.
• W4385709130 creator A5014593593 @default.
• W4385709130 creator A5019361798 @default.
• W4385709130 creator A5022201674 @default.
• W4385709130 creator A5027337972 @default.
• W4385709130 creator A5035830011 @default.
• W4385709130 creator A5042382574 @default.
• W4385709130 creator A5046037436 @default.
• W4385709130 creator A5058720193 @default.
• W4385709130 creator A5062177294 @default.
• W4385709130 creator A5068633346 @default.
• W4385709130 creator A5073555574 @default.
• W4385709130 creator A5074954208 @default.
• W4385709130 creator A5076439623 @default.
• W4385709130 creator A5079725698 @default.
• W4385709130 creator A5079805600 @default.
• W4385709130 creator A5080599763 @default.
• W4385709130 creator A5091903928 @default.
• W4385709130 creator A5092198182 @default.
• W4385709130 creator A5092394575 @default.
• W4385709130 creator A5092620962 @default.
• W4385709130 creator A5092620963 @default.
• W4385709130 creator A5092620964 @default.
• W4385709130 creator A5092620965 @default.
• W4385709130 creator A5092620966 @default.
• W4385709130 creator A5092620967 @default.
• W4385709130 creator A5092620968 @default.
• W4385709130 date "2023-08-09" @default.
• W4385709130 modified "2023-09-26" @default.
• W4385709130 title "Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review" @default.
• W4385709130 cites W1701253360 @default.
• W4385709130 cites W1931567285 @default.
• W4385709130 cites W2015644310 @default.
• W4385709130 cites W2072659926 @default.
• W4385709130 cites W2134678353 @default.
• W4385709130 cites W2204347289 @default.
• W4385709130 cites W2609502046 @default.
• W4385709130 cites W2624933871 @default.
• W4385709130 cites W2752005892 @default.
• W4385709130 cites W2799696340 @default.
• W4385709130 cites W2897055301 @default.
• W4385709130 cites W2914208637 @default.
• W4385709130 cites W2918271210 @default.
• W4385709130 cites W3005664566 @default.
• W4385709130 cites W3015705209 @default.
• W4385709130 cites W3026926823 @default.
• W4385709130 cites W3034312608 @default.
• W4385709130 cites W3041176328 @default.
• W4385709130 cites W3043628515 @default.
• W4385709130 cites W3044030772 @default.
• W4385709130 cites W3080556470 @default.
• W4385709130 cites W3081603667 @default.
• W4385709130 cites W3084695223 @default.
• W4385709130 cites W3085031248 @default.
• W4385709130 cites W3087791614 @default.
• W4385709130 cites W3087862874 @default.
• W4385709130 cites W3088256443 @default.
• W4385709130 cites W3088841124 @default.
• W4385709130 cites W3089890285 @default.
• W4385709130 cites W3091628978 @default.
• W4385709130 cites W3092307448 @default.
• W4385709130 cites W3093734139 @default.
• W4385709130 cites W3096392611 @default.
• W4385709130 cites W3103506925 @default.
• W4385709130 cites W3106790420 @default.
• W4385709130 cites W3109136263 @default.
• W4385709130 cites W3110319113 @default.
• W4385709130 cites W3110651980 @default.
• W4385709130 cites W3119329296 @default.
• W4385709130 cites W3120327534 @default.
• W4385709130 cites W3121554164 @default.
• W4385709130 cites W3125430479 @default.
• W4385709130 cites W3126641061 @default.
• W4385709130 cites W3126921596 @default.
• W4385709130 cites W3128420662 @default.
• W4385709130 cites W3130384115 @default.
• W4385709130 cites W3130933563 @default.
• W4385709130 cites W3131591676 @default.
• W4385709130 cites W3133477721 @default.
• W4385709130 cites W3134546283 @default.
• W4385709130 cites W3134823302 @default.
• W4385709130 cites W3135617626 @default.
• W4385709130 cites W3146142859 @default.
• W4385709130 cites W3155514722 @default.
• W4385709130 cites W3155911740 @default.
• W4385709130 cites W3156871407 @default.
• W4385709130 cites W3158066801 @default.
• W4385709130 cites W3160665713 @default.
• W4385709130 cites W3161855925 @default.
• W4385709130 cites W3164979194 @default.
• W4385709130 cites W3165012127 @default.
• W4385709130 cites W3166029810 @default.
• W4385709130 cites W3166753154 @default.
• W4385709130 cites W3168877626 @default.
• W4385709130 cites W3169182500 @default.
• W4385709130 cites W3172793935 @default.
• W4385709130 cites W3173861184 @default.
• W4385709130 cites W3174329580 @default.

• next